Usona Files Psilocybin NDA, Putting Two Psychedelics Before FDA

The nonprofit Usona Institute has completed a new drug application asking the Food and Drug Administration to approve its psilocybin formulation for major depressive disorder, according to reporting published Monday by Psychedelic Alpha — which would make it the second psychedelic application now sitting before the agency. Usona declined to comment, and neither the institute nor the FDA has confirmed that a submission was received.

The Wisconsin-based research organization has said little publicly about its regulatory progress for months. Psychedelic Alpha, which has tracked the program closely, reported the completed filing on Nov. 2 and said a decision could arrive in late 2026 under the most optimistic timelines, or very early next year.

A submission nobody announced

Usona's approach to disclosure has been notably quieter than that of Compass Pathways, the for-profit developer whose psilocybin program has become the public face of the field. Psychedelic Alpha reported that the institute declined to comment when reached on Monday, and that neither company nor agency had confirmed the filing by the time of publication.

What the reporting describes is a company in the post-submission phase rather than at the starting line: sources close to Usona, speaking on condition of anonymity, told Psychedelic Alpha that the institute is working with the FDA to answer the agency's questions and to design the risk evaluation and mitigation strategy, or REMS, that would govern how a psilocybin product is dispensed and monitored. The same reporting said FDA inspections have taken place at several Usona trial sites and at the institute's headquarters.

Two months, if the priority voucher holds

Both Usona and Compass hold Commissioner's National Priority Vouchers, a mechanism the agency has used to compress review of selected psychedelic programs toward a decision within roughly two months. Both programs also have breakthrough therapy designation and have been under rolling review, meaning sections of their applications were submitted and examined before the filings were complete.

That combination is why a psilocybin approval could plausibly land before the end of the year — a timetable that would have seemed implausible when psilocybin was still confined to Schedule I research protocols. For background on how the voucher pathway opened, see our earlier report on the FDA's psychedelic review push.

The second application already in the queue is not psilocybin at all. Resilient Pharmaceuticals, formerly Lykos Therapeutics, refiled its MDMA application for post-traumatic stress disorder over the summer after an earlier rejection, according to Psychedelic Alpha.

Compass answers within a day

On Tuesday, Compass said it expects to finalize its own rolling submission for COMP360 "in the next two weeks," according to BioSpace, with a launch targeted for the first half of next year. The company's shares fell Monday after the Usona report circulated, a reaction that reflects how much of Compass's valuation rests on being first to market.

The two filings are aimed at different patients. Usona's candidate, PSIL201, is being developed for major depressive disorder — the broad diagnosis that covers the largest share of people treated for depression. Compass's COMP360 targets treatment-resistant depression, a narrower group whose symptoms have not responded to multiple adequate trials of conventional antidepressants. BioSpace reported that both companies hold priority vouchers and that both could, in theory, be approved by the end of the year.

Major depressive disorder is one of the most common conditions seen in primary care, and current first-line treatment still runs through daily oral antidepressants and psychotherapy. Psilocybin's appeal to researchers is partly mechanistic: a small number of supervised dosing sessions, rather than a daily pill, with effects that in trials have appeared within days. Our coverage of recent multi-laboratory replication work on psilocybin's behavioral effects traces how much of that mechanism remains unsettled at the preclinical level.

What a filing does not mean

An accepted application is not an approval, and an approval would not by itself create access. Psilocybin remains a Schedule I substance, which means a federal rescheduling action would have to accompany any commercial launch — an administrative step that has tripped up other controlled-substance therapies. The REMS program under discussion would also shape who can prescribe, where dosing sessions happen and what training supervisors need.

For patients, the practical near-term answer is unchanged: psilocybin-assisted therapy outside a clinical trial is not a covered treatment option, and referral pathways for depression still run through established care. People interested in psychedelic-assisted treatment can ask about trial enrollment through academic medical centers, and mental health services remain the entry point for evaluation.

What to watch in the coming weeks is narrow and concrete. Compass's filing window closes within a fortnight. Usona's submission, if confirmed, sets a review clock that could produce the first FDA decision on a classic psychedelic — and the difference between a late-2026 decision and one in early 2027 now hinges on paperwork and inspection schedules rather than on clinical data.